Skip to main content

Table 1 Characteristics of patients with liver biopsy and of disease control patients

From: Rare incidence of methotrexate-specific lesions in liver biopsy of patients with arthritis and elevated liver enzymes

  Patients with liver biopsy Disease control patients Pvalues
Sex (female/male) 28/13 28/13 NS
Age (years) 52.2 ± 1.9 52.4 ± 1.9 NS
Rheumatic disease 25 RA; 8 SpA; 6 pSS; 2 CTD 25 RA; 8 SpA; 6 pSS; 2 CTD NS
Disease duration (years) 7.4 ± 1.1 10.5 ± 1.1 0.01
MTX exposure (weeks) 131.6 ± 26 277.9 ± 29.6 <0.001
MTX cumulative dose (mg) 1,287.8 ± 246.7 3,217.3 ± 368 <0.001
MTX weekly dose (mg/week) 10.9 ± 0.7 12.240 ± 0.7 NS
Shared epitope positivity 17/36 22/41 NS
Rheumatoid factor positivity 17/38 19/39 NS
Anti-CCP positivity 19/29 12/23 NS
  1. Data for 41 patients with liver biopsy compared with 41 subjects matched for age, sex and rheumatic disease from a population of 1,571 arthritis patients on long-term methotrexate (MTX) therapy. Data presented as n or mean ± standard error of the mean. CCP, cyclic citrullinated peptide; CTD, connective tissue disease; NS, not significant; pSS, primary Sjögren syndrome; RA, rheumatoid arthritis; SpA, spondylarthropathy.